Molecular Markers of Prognosis and Response to Therapy in Breast Cancer
The goal is to understand hereditary breast cancer in greater detail leading to a prospective clinical trial (one of the first of its kind in the country).
Dr. Rasmussen will:
1) expand clinical subtypes and refine genetic signatures for each subtype of previous gene expression profiles
2) design a prospective clinical trial based on these profiles, and
3) include known familial and hereditary breast cancer cases in order to determine which clinical subtype they belong to. Gene expression profiling promises to provide much more powerful diagnostic, diagnostic and therapeutically predictive tests and will influence patient care in the very near future.
Maine Cancer Foundation Grants to this Organization:
|2010||Evaluating MicroRNA's as Prognostic Determinants in Stage II Colon Cancer||$78,000||Research||Maine Center for Cancer Medicine|
|2008||Colorectal Cancer Screenings||$6,839||Screening||Maine Center for Cancer Medicine|
|2007||Toolkit for Colorectal Cancer||$4,800||Education||Maine Center for Cancer Medicine|
|2006||Molecular Predictors of Iressa Response in Lung Cancer Patients||$68,241||Research||Maine Center for Cancer Medicine|
|2006||Cancer Risk and Prevention||$1,862||Education||Maine Center for Cancer Medicine|
|2004||Molecular Markers of Prognosis and Response to Therapy in Breast Cancer||$70,500||Research||Maine Center for Cancer Medicine|
|2003||Molecular Indicators of Prognosis and Response to Therapy in Breast Cancer||$60,700||Research||Maine Center for Cancer Medicine|
|2001||Cancer Genetics Research||$87,000||Research||Maine Center for Cancer Medicine|